| Literature DB >> 25498305 |
Yan-Peng Zhang1, You-Dong Wan2, Tong-Wen Sun3, Quan-Cheng Kan4, Le-Xin Wang5.
Abstract
INTRODUCTION: Vitamin D deficiency is common in critically ill patients, and was reported to be associated with adverse outcomes. However, the effect of vitamin D deficiency on mortality in critically ill patients remains unclear.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25498305 PMCID: PMC4274763 DOI: 10.1186/s13054-014-0684-9
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Figure 1Flow chart of article selection. OR, odds ratio.
Main characteristics included in the meta-analysis
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
|
| Single-center, retrospective | Single-center, prospective | Single-center, prospective | Multi-center, prospective | Multi-center, prospective | Single-center, retrospective | Multi-center, retrospective |
|
| Austria | Turkey | China | Australia | Canada | USA | USA |
|
| Neurologic (30.2%), cardiac surgery (15.0%), respiratory disease (8.1%), trauma (5.8%), brain surgery (5.0%), infectious diseases, including sepsis at admission (4.4%) | Respiratory insufficiency (45%), organ dysfunctions (44%), invasive mechanical ventilation (44%), sepsis/septic shock (35.8%), renal replacement therapy (34%), nosocomial infection (35%) | Severe pneumonia with respiratory failure (47.2%), acute exacerbations of chronic obstructive pulmonary disease (19%), intra-abdominal infection (15.3%), mechanical ventilation (85.6%) | Cardiac (30%), infection/sepsis (26%), heart/lung/bone marrow transplant (21%), trauma (9%), metabolic (7%), neurological (7%) | Cardiovascular (14%), respiratory (29%), neurological (7%), metabolic (7%), gastrointestinal (3%), sepsis (5%), postoperative (35%) | Cardiac (4.8%), gastrointestinal (10.7%), metabolic (11.4%), neurological (12.5%), obstructive airway disease (13.7%), pulmonary (18.3%), others (10.9%), renal (5%), sepsis/septic shock (12.3%) | Medical (58.3%) Surgical (41.7%) |
|
| 655 | 201 | 216 | 100 | 196 | 437 | 2,399 |
|
| 394 (60.2%) | 139 (69.2%) | 95 (44.0%) | 24 (24.0%) | 50 (25.5%) | 340 (77.8%) | 637 (26.6%) |
|
| 412 (62.9%) | 113 (56.0%) | 120 (55.6%) | 65 (65.0%) | 121 (62.0%) | 208 (47.5%) | 1,030 (43.0%) |
|
| 65 (22)a | 66 (21)a | 64 (25)a | 52 ± 17b | 64 ± 14b | 56.6 ± 17.1b | 64.9 ± 16.6b |
|
| 26 (16)a (SAPS II) | 23(11)a (APACHE II) | 21(8)a (APACHE II) | 21 ± 8b (APACHE II) | 20.2 ± 7.8b (APACHE II) | 67.0 ± 27.5b (APACHE IV) | / |
|
| Deficient (<20 ng/ml), insufficient (≥20 and <30 ng/ml), normal (≥30 ng/ml) | Insufficient (<20 ng/ml), sufficient (≥20 ng/ml) | Deficient (<20 ng/ml), insufficient (≥20 and <30 ng/ml), sufficient (≥30 ng/ml) | Deficient (<10 ng/ml), insufficient(10 to 20 ng/ml), sufficient(>20 ng/ml) | Deficient (≤12 ng/ml), insufficient (>12 to ≤24 ng/ml), sufficient (>24 ng/ml) | deficient (<20 ng/ml), insufficient (≥20 and <30 ng/ml), sufficient (≥30 ng/ml) | deficient(≤15 ng/mL, insufficient (16 to 29 ng/mL, sufficient (≥30 ng/ mL) |
|
| ICU and hospital mortality, ICU and hospital LOS | ICU mortality | Hospital mortality | Hospital mortality, ICU and hospital LOS | Hospital mortality, time-to-alive ICU discharge | Hospital mortality, hospital LOS | 30-day, 90-day, 365-day, and in-hospital morality |
|
| 7 | 6 | 6 | 7 | 7 | 6 | 7 |
aMedian (interquartile range); bmean ± SD; cNewcastle-Ottawa scales (NOS). SAPS, simplified acute physiology score; APACHE, acute physiology and chronic health evaluation; LOS, length of stay.
Figure 2Forest plot showing the effect of vitamin D deficiency on hospital mortality. OR, odds ratio.
Figure 3Forest plot showing the effect of vitamin D deficiency on ICU mortality. OR, odds ratio.
ICU length of stay among studies
|
|
|
|
|
|---|---|---|---|
|
| 2014 | Deficiency, <20 ng/ml | 6.9 (9.8)a |
| insufficiency, 20 to 30 ng/ml | 4.9 (7.7)a | ||
| sufficiency, >30 ng/ml | 5.2 (6.5)a | ||
|
| 2013 | Insufficiency, <20 ng/ml | 9 (5, 14)b |
| sufficiency, ≥20 ng/ml | 8 (5, 13)b | ||
|
| 2013 | Deficiency, <20 ng/ml | 10.5 (6.8, 25.3)b |
| insufficiency, 20 to 30 ng/ml | 8.6 (6.9, 20.5)b | ||
| sufficiency, >30 ng/ml | 15.2 (10.3, 23.6)b | ||
|
| 2012 | Deficiency, <10 ng/ml | 12 (2, 14)b |
| insufficiency,10 to 20 ng/ml | 7 (4, 15)b | ||
| sufficiency, >20 ng/ml | 4 (3, 10)b | ||
|
| 2012 | Deficient, ≤12 ng/ml | 10.6 ± 8.4c |
| insufficient, 12 to 24 ng/ml | 6.8 ± 6.0c | ||
| sufficient, >24 ng/ml | 5.9 ± 5.4c | ||
|
| 2011 | Deficiency, <20 ng/ml | 4.3 ± 4.5c |
| insufficiency, 20 to 30 ng/ml | 3.7 ± 3.9c | ||
| sufficiency, >30 ng/ml | 4.2 ± 3.7c | ||
|
| 2011 | - | - |
aMedian (interquartile range); bmedian (Q1, Q3); cmean ± SD.
Subgroup and sensitivity analyses for hospital mortality
|
|
|
|
|
|
|---|---|---|---|---|
|
| ||||
| Total [ | 7 | 1.76 (1.38, 2.24) | 0.402 | 2.3% |
| 25(OH)D level as a cutoff for vitamin D deficiency | ||||
| 20 ng/ml [ | 3 | 2.12 (1.35, 3.34) | 0.198 | 38.3% |
| 15 ng/ml [ | 1 | 1.72 (1.27, 2.33) | - | - |
| 12 ng/ml [ | 1 | 1.12 (0.45, 2.70) | - | - |
| 10 ng/ml [ | 1 | 1.13 (0.18, 7.27) | - | - |
|
| ||||
| Multicenter [ | 3 | 1.63 (1.23, 2.17) | 0.623 | 0.0% |
| Prospective cohort [ | 3 | 1.83 (1.03, 3.24) | 0.241 | 29.7% |
| One-study-out method | ||||
| Amrein [ | 1 | 1.79 (1.23, 2.70) | 0.284 | 20.5% |
| Hu [ | 1 | 1.67 (1.30, 2.15) | 0.511 | 0.0% |
| Nair [ | 1 | 1.77 (1.39, 2.26) | 0.298 | 18.3% |
| Higgins [ | 1 | 1.82 (1.42, 2.34) | 0.396 | 1.8% |
| Venkatram [ | 1 | 1.72 (1.35, 2.19) | 0.571 | 0.0% |
| Braun [ | 1 | 1.82 (1.23, 2.70) | 0.281 | 21.0% |
| Fixed-effects versus random-effects model method | ||||
| Fixed-effects model | 6 | 1.76 (1.38, 2.24) | 0.402 | 2.3% |
| Random-effects model | 6 | 1.76 (1.37, 2.26) | 0.402 | 2.3% |
25(OH)D, 25-hydroxyvitamin D.